Source: Annual Congress 2005 - Cystic fibrosis lung disease: let's make things better
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Haeussermann, P. Brand, A. Fischer, T. Meyer, B. Muellinger, J. Seitz, K. Sommerer, J. Stegemann, B. Wachall, G. Scheuch (Gauting, Gemuenden, Heppenheim, Germany). Intrapulmonal deposition of two different tobramycin formulations. Eur Respir J 2005; 26: Suppl. 49, 4640

Member's Comments

No comment yet.

Related content which might interest you: In-vitro comparison of tobramycin nebulised using two different nebuliser systems Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis Source: Eur Respir Rev 2013; 22: 476-486 Year: 2013 Comparative efficacy of different methods of ceftazidime administration in children with cystic fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 126s Year: 2001 Once-daily tobramycin in the treatment of adult patients with cystic fibrosis Source: Eur Respir J 2002; 19: 303-309 Year: 2002 Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010 Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009 Comparison of the Pharmacokinetics of a child-friendly Fixed-Dose Combination of rifampin and isoniazid and separate tablets in children with pulmonary tuberculosis. Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease Year: 2021 Relative lung deposition of tobramycin from a MicroAir nebuliser Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006 Long-term administration of aerosolised tobramycin in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 619s Year: 2005 A novel submicron budesonide suspension demonstrates equivalent nebulization times compared to cyclodextrin-based solution formulations Source: Annual Congress 2008 - Wheezing in preschool children Year: 2008 Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011 In-vitro deposition study of a levofloxacin (LEV) solution into a novel human nasal cast model by the PARI VibrENTÔ Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 The effect of nebulizer systems in inhaled tobramycin Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Pharmacokinetics and pharmacoynamics of clarithromycin in the empyema pleural fluid Source: Eur Respir J 2004; 24: Suppl. 48, 637s Year: 2004 In vitro lung deposition evaluation of liposomal Amphotericin B with 6 different nebulizer systems Source: Eur Respir J 2002; 20: Suppl. 38, 16s Year: 2002 A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis Source: Eur Respir J 2002; 20: 658-664 Year: 2002 Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 Combination therapy with intrapleural doxycycline and talc in reduced doses for pleurodesis Source: Annual Congress 2012 - Clinical issues in malignant pleural effusions Year: 2012 Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum pseudomonas aeruginosa density in non-CF bronchiectasis Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa Year: 2009 Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules Source: Eur Respir J, 54 (6) 1900580; 10.1183/13993003.00580-2019 Year: 2019